PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30675160-3 2018 Vanadyl sulfate (VS) has been investigated as a hypoglycemic compound in animal and human studies showing effective insulin-mimetic properties. vanadyl sulfate 0-15 insulin Homo sapiens 116-123 24668346-3 2014 Among the six compounds examined, only [V(IV)(pdbh)2], [V(IV)(cat)3](2-) and [V(IV)(hyph(Ph))2], which at the physiological pH convert to the corresponding V(IV)O complexes, were found to exhibit a significant insulin-mimetic activity compared to VOSO4. vanadyl sulfate 247-252 insulin Homo sapiens 210-217 14622970-0 2003 Prolongation of insulin-induced activation of mitogen-activated protein kinases ERK 1/2 and phosphatidylinositol 3-kinase by vanadyl sulfate, a protein tyrosine phosphatase inhibitor. vanadyl sulfate 125-140 insulin Homo sapiens 16-23 14622970-1 2003 Vanadium salts such as vanadyl sulfate (VS), potent inhibitors of protein tyrosine phosphatases, have been shown to mimic, augment, and prolong insulin"s action. vanadyl sulfate 23-38 insulin Homo sapiens 144-151 12500990-0 2002 Effect of acute and short-term administration of vanadyl sulphate on insulin sensitivity in healthy active humans. vanadyl sulfate 49-65 insulin Homo sapiens 69-76 12800089-8 2003 Finally, treatment of L6 cells with subtherapeutic amounts of vanadyl sulfate and rapamycin induced a synergistic 3-fold increase in insulin-induced glucose uptake at 2 hours. vanadyl sulfate 62-77 insulin Homo sapiens 133-140 12679171-6 2003 Treating HepG2 cells with other minerals known to have insulin-sensitizing effects such as magnesium (1 mM), zinc (0.2 mM), and vanadyl sulfate (0.1 mM) significantly reduced apoA-I promoter activity in the presence and absence of 100 microU/mL of insulin. vanadyl sulfate 128-143 insulin Homo sapiens 55-62 12679171-6 2003 Treating HepG2 cells with other minerals known to have insulin-sensitizing effects such as magnesium (1 mM), zinc (0.2 mM), and vanadyl sulfate (0.1 mM) significantly reduced apoA-I promoter activity in the presence and absence of 100 microU/mL of insulin. vanadyl sulfate 128-143 insulin Homo sapiens 248-255 12500990-2 2002 The purpose of the present study was to examine whether the effects of acute and short-term administration of vanadyl sulfate (VA) on insulin sensitivity also exist in healthy active individuals. vanadyl sulfate 110-125 insulin Homo sapiens 134-141 12500990-2 2002 The purpose of the present study was to examine whether the effects of acute and short-term administration of vanadyl sulfate (VA) on insulin sensitivity also exist in healthy active individuals. vanadyl sulfate 127-129 insulin Homo sapiens 134-141 11238540-8 2001 Vanadyl sulfate also caused a modest increase in insulin-mediated glucose disposal (from 4.3 +/- 0.4 to 5.1 +/- 0.6 mg/kg lean body mass x min; P< 0.03), although the improvement in insulin sensitivity did not correlate with the decline in FPG after treatment (r = -0.16; P = NS). vanadyl sulfate 0-15 insulin Homo sapiens 49-56 11238540-1 2001 Vanadyl sulfate (VOSO(4)) is an oxidative form of vanadium that in vitro and in animal models of diabetes has been shown to reduce hyperglycemia and insulin resistance. vanadyl sulfate 0-15 insulin Homo sapiens 149-156 11238540-1 2001 Vanadyl sulfate (VOSO(4)) is an oxidative form of vanadium that in vitro and in animal models of diabetes has been shown to reduce hyperglycemia and insulin resistance. vanadyl sulfate 17-24 insulin Homo sapiens 149-156 11238540-8 2001 Vanadyl sulfate also caused a modest increase in insulin-mediated glucose disposal (from 4.3 +/- 0.4 to 5.1 +/- 0.6 mg/kg lean body mass x min; P< 0.03), although the improvement in insulin sensitivity did not correlate with the decline in FPG after treatment (r = -0.16; P = NS). vanadyl sulfate 0-15 insulin Homo sapiens 185-192 9578588-1 1998 Salts of the trace element vanadium, such as sodium orthovanadate and vanadyl sulfate (VS), exhibit a myriad of insulin-like effects, including stimulation of glycogen synthesis and improvement of glucose homeostasis in type I and type II animal models of diabetes mellitus. vanadyl sulfate 70-85 insulin Homo sapiens 112-119 10520409-7 1999 Vanadyl sulfate may also improve insulin sensitivity but there is no long term human studies. vanadyl sulfate 0-15 insulin Homo sapiens 33-40 9578588-1 1998 Salts of the trace element vanadium, such as sodium orthovanadate and vanadyl sulfate (VS), exhibit a myriad of insulin-like effects, including stimulation of glycogen synthesis and improvement of glucose homeostasis in type I and type II animal models of diabetes mellitus. vanadyl sulfate 87-89 insulin Homo sapiens 112-119 8621019-0 1996 Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. vanadyl sulfate 5-20 insulin Homo sapiens 30-37 8621019-7 1996 In contrast, in NIDDM subjects, vanadyl sulfate increased GIR approximately 82% (17.3 +/- 4.7 to 30.9 +/- 2.7 micromol / kg FFM / min, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of Rd (26.0 +/-4.0 vs. 33.6 +/- 2.22 micromol / kg FFM / min, P < 0.05) and enhanced suppression of HGO (7.7 +/- 3.1 vs. 1.3 +/- 0.9 micromol / kg FFM / min, P < 0.05). vanadyl sulfate 32-47 insulin Homo sapiens 169-176 8621019-8 1996 Increased insulin-stimulated glycogen synthesis accounted for >80% of the increased Rd with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. vanadyl sulfate 95-110 insulin Homo sapiens 10-17 8621019-11 1996 In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin"s inhibitory effect on lipolysis. vanadyl sulfate 35-50 insulin Homo sapiens 162-169 8621019-11 1996 In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin"s inhibitory effect on lipolysis. vanadyl sulfate 35-50 insulin Homo sapiens 162-169 8621019-12 1996 These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM. vanadyl sulfate 24-39 insulin Homo sapiens 64-71 7769096-0 1995 Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. vanadyl sulfate 5-20 insulin Homo sapiens 53-60